The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...

Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...

Rybelsus (oral semaglutide by Novo Nordisk) is used for type 2 diabetes, so the expense is usually ongoing, not a one-time ...

Tirzepatide can cost $500 to $1,900 a month without insurance. More affordable tirzepatide alternatives include semaglutide, ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

The Delhi High Court has allowed Dr Reddy’s to manufacture and export its semaglutide-based weight-loss drug. Semaglutide is the active ingredient in Novo Nordisk products such as Ozempic, Wegovy and ...

Novo Nordisk NVO reported disappointing top-line data from the two-year primary analysis of two late-stage studies evaluating Rybelsus (oral semaglutide 14 mg) for early-stage symptomatic Alzheimer’s ...

FDA approves first oral GLP-1 agonist to lower heart attack and stroke risk in diabetics SOUL trial shows 14% drop in major cardiovascular events with Rybelsus Targets arterial inflammation and ...

https://www.thehindubusinessline.com/news/national/obesity-products-take-centre-stage-in-india-and-abroad/article70253562.ece Copy Anti-obesity and diabetes products ...

Great news for heart health! The FDA has given the green light for Rybelsus, the first pill-form GLP-1 drug, to help manage cardiovascular risks in adults. This means a needle-free way to fight ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning for anyone taking Ozempic, Wegovy, Rybelsus, or Mounjaro. The health body made the appeal on social media for anyone ...